Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active
metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with
and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP
pMDI plus formoterol pMDI licensed products; this will be additionally compared to the
systemic exposure in adults without the spacer device.